OTC Markets OTCPK - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

6.88
0.00
(0.00%)
At close: May 9 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVBXF

Recent News: IVBXF

View More
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
PR Newswire 3 days ago
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
PR Newswire 4 days ago
Asian Market Insights With 3 Stocks Estimated Below Intrinsic Value

Asian Market Insights With 3 Stocks Estimated Below Intrinsic Value
Simply Wall St. 4 days ago
Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
PR Newswire 10 days ago
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
PR Newswire 12 days ago
Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
PR Newswire 14 days ago
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting

Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
PR Newswire 16 days ago
High Growth Tech Stocks In Asia For April 2025

High Growth Tech Stocks In Asia For April 2025
Simply Wall St. 24 days ago
3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%

3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%
Simply Wall St. last month
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire last month
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
PR Newswire last month
View More

Related Tickers

WHWK Whitehawk Therapeutics, Inc.
1.7000
+3.66%
 
ZLDPF Zealand Pharma A/S
64.38
0.00%
 
VIRX Viracta Therapeutics, Inc.
0.0188
+10.59%
 
SANN.SW Santhera Pharmaceuticals Holding AG
13.18
-0.15%
 
IPSC Century Therapeutics, Inc.
0.5370
+3.27%
 
OVID Ovid Therapeutics Inc.
0.2901
-1.33%
 
ANTX AN2 Therapeutics, Inc.
1.2000
-1.64%
 
AVIR Atea Pharmaceuticals, Inc.
2.7200
-1.45%
 
ZBIO Zenas BioPharma, Inc.
9.05
-2.58%
 
SLRN Acelyrin, Inc.
2.3600
-4.07%